SYR-472 Open-label Study
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: SYR-472
- Registration Number
- NCT01751360
- Lead Sponsor
- Takeda
- Brief Summary
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
- The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.
Read More
Exclusion Criteria
-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease
. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description SYR-472 100mg SYR-472 SYR-472 100mg
- Primary Outcome Measures
Name Time Method Blood Glucose 7 days Blood Glucose
- Secondary Outcome Measures
Name Time Method